Regeneron Pharmaceuticals Q3 FY25: where the revenue came from and where it went
The whole income statement of Regeneron Pharmaceuticals for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2025
- Reported
- Oct 28, 2025
Revenue$3.75B
+1% year over year
Gross profit$3.16B
84% margin
Operating profit$1.03B
27% margin
Net profit$1.46B
39% margin
Net profit is larger than what operations earned, because the statement adds $0.74B below it, under Other income, net.
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 3.75 | 100% | +1% |
| Collaboration | 1.97 | 53% | +19% |
| Product | 1.59 | 42% | −18% |
| Service other | 0.20 | 5% | +74% |
| Other products | <0.01 | 0% | |
| Cost of revenue | −0.60 | 16% | |
| Gross profit | 3.16 | 84% margin | −1pp |
| R&D | −1.48 | 39% | +5pp |
| SG&A | −0.66 | 18% | −2pp |
| Operating profit | 1.03 | 27% margin | −4pp |
| Other income, net | 0.74 | ||
| Tax | −0.30 | ||
| Net profit | 1.46 | 39% margin | +3pp |
236 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest